After 8 cycles of PD-1 inhibitor pembrolizumab (200 mg on day 1) combined with gemcitabine (1.4 g on day 1, every 8 days) therapy, both the retroperitoneal metastatic lesions and ureteral tumor significantly decreased in size. The gene discussed is PDCD1; the disease is ureter neoplasm.